Biopharma heavy hitters convened at the Galien Forum in New York City, offering tips and guidance for the leaders of tomorrow.

Executives at Big Pharma and small biotech will be rewarded in 2024 if they can find new ways to develop and commercialize drugs in the context of an unforgiving investment, payer, and regulatory landscape.

Executives responding to this year’s finance and funding outlook questions are optimistic about the potential for a turnaround in 2024.

Biopharmaceutical companies can’t afford to halt production lines due to manufacturing violations next year. Manufacturing and supply chain processes will require fresh thinking and flexibility in 2024.

Krystal Biotech's side business is an aesthetics company, Jeune Aesthetics, that uses the same platform and viral vector as Krystal to deliver collagen genes to consumers seeking aesthetic improvement.

Krish and Krishnan, the husband-and-wife team that founded and leads Krystal Biotech, cleared a path to market for the first ever topical and redosable gene therapy.

In the challenging development space for novel antibiotics, Spero Therapeutics is using partnership, external validation, and formulation science to develop drugs treating bacterial infections both rare and common.

For Krish and Suma Krishnan, the husband-and-wife leadership team at Krystal Biotech, bringing work home, and bringing home to work, is inevitable. A larger shared goal smooths the edges. 

To adopt and use new technology effectively, leaders should focus on people and their problems, not the technology itself, according to former Google executive turned biotech CEO.